• Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
Thursday, November 19, 2026
No Result
View All Result
Subscribe Now
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Trump’s Deal Turns Sour as Voters Withdraw Support

    Trump’s Deal Turns Sour as Voters Withdraw Support

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
The Insight Post
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Trump’s Deal Turns Sour as Voters Withdraw Support

    Trump’s Deal Turns Sour as Voters Withdraw Support

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
No Result
View All Result
No Result
View All Result
Home Europe

Keeping an eye on AI-powered drugs

by Theinsightpost
December 29, 2023
in Europe
0 0
0
Keeping an eye on AI-powered drugs

Medicines created using artificial intelligence could be coming to a pharmacy counter near you — but just how soon depends on whether they live up to the hype in clinical tests.

AI may have become the buzzword of 2023, but major pharmaceutical companies and startups alike have been investing in the tech for years.

In 2020, Britain-based Exscientia became the first company to launch human tests for an AI-designed drug molecule, with the hopes of treating obsessive-compulsive disorder.

Since then, dozens of AI-powered drugs have entered clinical trials, and many more are on the way.

If these tests are successful, AI could upend the drug discovery process. Researchers typically spend years sifting through troves of data and test results to land on promising drug candidates in the lab — only for many to fail during clinical trials.

AI models could improve the odds by helping researchers identify the right target in the body for a particular disease, then find or even create the right molecule to interact with it, and lastly, predict which patients it could help. Pharma companies could then invest in only the most favorable options, cutting out much of the early trial and error.

It isn’t a surefire strategy: Exscientia’s OCD trial, for example, shuttered in 2021 after failing to meet its targets. But ultimately, the goal is to bring cheaper medicines to patients faster, while bringing in billions of dollars in profits.

“Just from drug discovery to clinical development, that span is about five and a half years,” said Aarti Chitale, a senior industry analyst for health care and life sciences at the advisory firm Frost & Sullivan. “Some of the leading AI vendors are able to bring that duration down to only about 18 months.”

Money pours in

Investors have taken note of the opportunity, pouring at least $10bn[€9.1bn] into startups targeting AI in early drug development since 2019, while European pharma giants have announced major deals to expand their AI capabilities.

France’s Sanofi, for example, inked a $1.2bn [€1.1bn] pact with Atomwise to sort through small molecules in 2022, while the British-Swedish AstraZeneca expanded its partnership with the United Kingdom’s BenevolentAI to hunt for treatments for systemic lupus erythematosus and heart failure, in addition to chronic kidney disease and idiopathic pulmonary fibrosis.

As of 2022, there were nearly 270 companies working on AI-powered drug discovery around the world, with Western Europe serving as a growing hub, according to consultancy firm McKinsey & Co.

“We believe that there is huge promise from artificial intelligence in terms of medicines development,” said Peter Arlett, head of data analytics and methods for European Medicines Agency, which oversees pharmaceutical products for the European Union.

Notably, the use of AI for drug discovery is generally considered low-risk because if a potential medicine fails, it fails in a simulation, not a patient. Instead, AI likely poses a greater risk in later stages of drug development given the potential for ethical issues, risks of human biases to work their way into algorithms or flawed data analyses that are used in a drug’s application for regulatory approval.

Regulating pharma AI

As pharmaceutical companies lean more heavily on AI across the therapeutic pipeline, regulators are catching up to ensure these tools are used safely. The EMA published a draft paper this summer on the path forward for AI in drug development, and will hold a workshop in November to solicit feedback from the pharma sector and other stakeholders.

“We see it as the start, the very start, of [AI] guidance and regulation in the pharmaceutical sector,” said Arlett, who is also co-chair of the EMA’s Big Data Steering Group.

The reflection paper is set to be finalised by late 2024, but it will likely “change significantly” before then based on external feedback, Arlett said. While the document won’t be binding, it will offer a more concrete picture of the regulatory guidance to come in 2025 or 2026, which pharma companies will be expected to follow.

Heading into the November workshop, Arlett said regulators broadly agree that they should categorise the risks of AI for different purposes so that “we don’t over-regulate where the use of AI may be just a background process, and not impact the benefit-risk balance for a medicine.”

Sign up for EUobserver’s daily newsletter

All the stories we publish, sent at 7.30 AM.

By signing up, you agree to our Terms of Use and Privacy Policy.

Even so, he said regulators should have at least some access to drugmakers’ algorithms and the data used to train their models during the discovery process, as well as insight into how algorithms are used to manage medicines after they’ve been authorised — for example, if an algorithm helps to determine a patient’s insulin dosages, the EMA wants to know how it works. The level of transparency that will be required is still up for debate.

“Because the algorithm is learning, we will need probably to think innovatively as to how we oversee that,” Arlett said. “The existing framework, which is rather strict and very structured … may not be optimal for something that’s as fast-moving as a learning algorithm.”

The industry responds

The pharma industry is keeping tight-lipped ahead of the November workshop, though executives from some leading firms, including Exscientia, have pushed back against proposals to establish AI-specific drug discovery regulations.

In a statement, the Brussels-based trade group European Federation of Pharmaceutical Industries and Associations said that new AI policies should “balance benefits and risks of AI while supporting and fostering innovation,” and that “we already have a robust framework for handling statistical and predictive models and software that will apply to many uses of AI in medicines development.”

Regardless of looming changes to the regulatory landscape, drugmakers still need to figure out how to bring AI-powered medicines to market — and prove that they’re more beneficial than existing treatments. Ultimately, clinical success will be the key determinant for how widely AI is used for drug discovery, rather than time or cost savings, as noted by the Boston Consulting Group.

Transforming pharma

The industry faces some other challenges, too. AI and machine learning models need robust, high-quality datasets to work well, and a central repository for drugmakers doesn’t yet exist in Europe. Further, most investment in the past five years has been in high-income countries and focused on the profitable fields of oncology and neurology, leaving infectious diseases — which carry a much greater health burden globally — underinvested in, excluding Covid-19.

Global economic uncertainty could also slow progress for smaller firms and startups, Chitale said. While venture capital funding for AI-powered drug discovery startups soared in 2021, reaching $4.7bn [€4.3bn], that level was much lower in 2022 and 2023, in line with a broader investment slowdown, according to analytics firm CB Insights.

Even so, industry players, academics and funders believe AI is poised to transform the pharma sector. In a recent survey, 84 percent of those currently using AI said they expect it to play a significant role in drug discovery over the next five years, compared with 70 percent among those not using AI.

In Europe, the use of AI isn’t limited to the early stages of research into potential blockbuster medicines. EFPIA, the drug industry trade group, said major pharma companies are “employing AI and ML approaches across the entire lifecycle of medicines development” — from drug discovery and manufacturing to safety monitoring and beyond.

ShareTweetSend
Previous Post

More Samsung Galaxy S24, S24+, and S24 Ultra renders arrive

Next Post

Put in and drawback techniques

Related News

Azerbaijani and Georgian Delegates Convene for Strategic Discussions during “Eternity-2026” Exercise
Europe

Azerbaijani and Georgian Delegates Convene for Strategic Discussions during “Eternity-2026” Exercise

November 19, 2026
The Coalition of the Willing: Seizing the Opportunity for Impactful Action
Europe

The Coalition of the Willing: Seizing the Opportunity for Impactful Action

November 19, 2026
EU Unveils €45 Billion Loan Proposal for Ukraine Amid High-Stakes Meeting of Trump, Xi, and Putin
Europe

EU Unveils €45 Billion Loan Proposal for Ukraine Amid High-Stakes Meeting of Trump, Xi, and Putin

November 18, 2026
Moscow Asserts It Will Respect EU Delegation’s Autonomy in Ukraine Negotiations
Europe

Moscow Asserts It Will Respect EU Delegation’s Autonomy in Ukraine Negotiations

November 15, 2026
Next Post

Put in and drawback techniques

Discussion about this post

Subscribe To Our Newsletters

    Customer Support


    1251 Wilcrest Drive
    Houston, Texas
    77042 USA
    Call-832.795.1420
    e-mail – news@theinsightpost.com

    Subscribe To Our Newsletters

      Categories

      • Africa
      • Africa-East
      • African Sports
      • American Sports
      • Arts
      • Asia
      • Australia
      • Business
      • Business Asia
      • Business- Africa
      • Canada
      • Defense
      • Education
      • Egypt
      • Energy
      • Entertainment
      • Europe
      • European Soccer
      • Finance
      • Germany
      • Ghana
      • Health
      • Insight
      • International
      • Investing
      • Japan
      • Latest Headlines
      • Life & Living
      • Markets
      • Mobile
      • Movies
      • New Zealand
      • Nigeria
      • Politics
      • Scholarships
      • Science
      • South Africa
      • South America
      • Sports
      • Tech
      • Travel
      • Travel-Africa
      • UK
      • USA
      • Weather
      • World
      No Result
      View All Result

      Recent News

      Putin Promises Consequences Following Ukraine’s Assault on Kerch Strait Bridge

      Putin Promises Consequences Following Ukraine’s Assault on Kerch Strait Bridge

      November 19, 2026
      Brian Blessed Shares Amusing Encounter with Female Gorillas at Zoo

      Brian Blessed Shares Amusing Encounter with Female Gorillas at Zoo

      November 19, 2026
      Unveiling the Real Narrative: ‘The Altruists’ and Their Connection to the FTX Controversy

      Unveiling the Real Narrative: ‘The Altruists’ and Their Connection to the FTX Controversy

      November 19, 2026
      Is Hakeem Jeffries Facing a Moment of Crisis?

      Is Hakeem Jeffries Facing a Moment of Crisis?

      November 19, 2026
      • Home
      • Advertise With Us
      • About Us
      • Corporate
      • Consumer Rewards
      • Forum
      • Privacy Policy
      • Social Trends

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      Welcome Back!

      Login to your account below

      Forgotten Password?

      Retrieve your password

      Please enter your username or email address to reset your password.

      Log In

      Add New Playlist

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in .

      No Result
      View All Result
      • Home
      • Insight
      • Blog
      • Business
      • Entertainment
      • Health
      • Politics
      • Shop
        • Gift Shop
        • Value Shop
        • Store
        • Bargain Shop
        • Discount
      • Sports
      • Tech
      • Travel
      • USA
      • Video
      • World
        • Asia
        • Africa
        • South America
        • North America
        • Europe
        • Oceania

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      The Insight Post
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      Cookie Policy

      More information about our Cookie Policy